A Phase I/II Trial of Post-Prostatectomy Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3NO Prostate Cancer.

At a glance
Trial Overview
Trial Details
- Identifiers
- Other Details
Interventions
Trial Centres
- Investigators
- Centres
Trial History
References

Trial Profile

A Phase I/II Trial of Post-Prostatectomy Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3NO Prostate Cancer.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bicalutamide; Docetaxel; Goserelin; Leuprorelin
Indications Prostate cancer
Focus Adverse reactions

Most Recent Events

24 Jul 2019 Biomarkers information updated
17 Aug 2013 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center, 4P06-3).
28 Aug 2012 Planned end date changed from 1 Sep 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com